
    
      OSI-906 is a new agent that inhibits the insulin-like growth factor receptor pathway.
      Targeting this pathway appears to be a promising strategy to treat cancer based on laboratory
      studies. The present study will test if this agent can be administered safely in combination
      with pemetrexed, a commonly used chemotherapeutic agent.
    
  